Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Antimicrobial Resistance & Infection Control

Fig. 2

From: Antibiotic utilisation and resistance over the first decade of nationally funded antimicrobial stewardship programmes in Singapore acute-care hospitals

Fig. 2

Trends in antibiotic utilisation rate (daily defined doses per 1,000 inpatient-days) across five public acute-care hospitals for (A) All broad-spectrum antibiotics, (B) Anti-pseudomonal antibiotics, (C) Third-generation cephalosporins, (D) Carbapenems, (E) Quinolones, (F) Beta-lactam/beta-lactamase inhibitors, first half of 2011 to second half of 2020. The | symbols denote the joinpoints identified using joinpoint regression analysis. Anti-pseudomonal antibiotics comprise cefepime, ceftazidime, ciprofloxacin, colistin, doripenem, imipenem, meropenem, levofloxacin, piperacillin-tazobactam and polymyxin B. Third generation cephalosporins comprise ceftazidime and ceftriaxone. Carbapenems comprise ertapenem, imipenem, meropenem and doripenem. Quinolones comprise ciprofloxacin, levofloxacin and moxifloxacin. Beta-lactam/beta-lactamase inhibitors comprise amoxicillin-clavulanate and piperacillin-tazobactam

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us